Claims
- 1. Use of an estriol mono-sulfamate according to formula I
- 2. Use according to claim 1, wherein the estriol mono-sulfamate is estriol-3-O-sulfamate.
- 3. Use according to claim 1 or 2, wherein the mammal is a human.
- 4. Use according to any one of claims 1 to 3, wherein the autoimmune disease involves a Th1-mediated immune response.
- 5. Use according to any one of claims 1 to 4, wherein the disease is selected from the group consisting of multiple sclerosis, rheumatoid arthritis, juvenile oligoarthritis, type 1 diabetes mellitus; inflammatory bowel disease, Hashimoto's thyroiditis, Addison's disease, lupus disorders, acute graft-versus-host disease, Crohn's disease.
- 6. Use according to any one of claims 1 to 5, wherein the disease is multiple sclerosis.
- 7. Use according to any one of claims 1 to 6, wherein the estriol mono-sulfamate is administered in a cumulative dose of 5-500 mg per month.
- 8. Use according to any one of claims 1 to 7, wherein treatment further comprises the administration of a second therapeutic agent.
- 9. Use according to any one of claims 1 to 8, wherein the medicament is to be administered orally.
- 10. Use of estricl mono-sulfamate for the manufacture of a medicament for providing a blood level of estriol as observed during the late pregnancy in a woman.
- 11. Use according to claim 10, wherein the estriol mono-sulfamate is estriol-3-O-sulfamate.
Priority Claims (1)
Number |
Date |
Country |
Kind |
02090161.7 |
Apr 2002 |
EP |
|
Parent Case Info
[0001] This application claims the benefit of the filing date of U.S. Provisional Application Serial No. 60/359,650 filed Feb. 27, 2002.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60359650 |
Feb 2002 |
US |